PBLS Parabilis Medicines, Inc.

Price Chart

Executive Summary

Parabilis Medicines completed its IPO and simultaneously closed a $75M private placement with Regeneron at a 10% discount to the IPO price, issuing 4,166,666 shares. The company also adopted a classified board, supermajority vote requirements for director removal and bylaw amendments, and exclusive forum provisions. The Regeneron investment provides a strong strategic endorsement and capital, but the governance changes entrench the board and limit shareholder rights.

Key Financial Metrics

Actionable Insight

Key Facts

• Regeneron purchased $75M of PBLS common stock at 90% of the $20.00 IPO price, or $18.00 per share.
• The private placement closed concurrently with the IPO on June 11, 2026.
• 4,166,666 shares were issued to Regeneron in the private placement.
• The company adopted a classified board with three-year staggered terms for directors.
• Directors may only be removed for cause by a 2/3 supermajority vote.
• Stockholder action by written consent is eliminated (except for preferred stock).
• Special meetings may only be called by the board, not by stockholders.
• Bylaw amendments by stockholders require a 2/3 supermajority unless the board recommends the change.
• The charter authorizes 800M shares of common stock (600M voting, 200M non-voting) and 10M shares of undesignated preferred stock.
• Exclusive forum provisions designate Delaware Chancery Court for internal corporate claims and federal district courts for Securities Act claims.

Financial Impact

$75M capital infusion at a 10% discount to the IPO price, representing a ~4.2% stake based on the 100M shares outstanding post-IPO (assuming the IPO was 16.7M shares at $20 for ~$333M gross proceeds).

Risk Factors

• Governance entrenchment may deter activist investors and could lead to a governance discount in the stock.
• Regeneron's 4.99% beneficial ownership limitation on conversion of non-voting stock could limit liquidity and voting power alignment.
• The 10% discount to IPO price for Regeneron represents immediate dilution to public IPO investors.
• Classified board and supermajority requirements make it difficult for shareholders to effect change.

Market Snapshot

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

US Market Status

Related Tickers